Loading
A phase 2 trial of Zamtocabtagene autoleucel in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.
DALY II Japan/MB-CART2019.1 for DLBCL is a phase 2 interventional study registered as NCT07288879 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-12-11 and due to reach its primary completion in 2027-01-31. Interventions recorded: MB-CART2019.1. Conditions listed: DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy. No results are recorded here; the registry entry is the source.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.